#112 – Say It Ain't Steno: Stenotrophomonas maltophilia Review
Feb 28, 2025
auto_awesome
Dr. Amy Mathers, a microbiology expert and IDSA guidance author, joins Dr. Julie Ann Justo, a clinical pharmacist specializing in infectious diseases, for an insightful discussion. They explore the challenges of treating Stenotrophomonas maltophilia, a tricky pathogen known for its resistance. The conversation delves into effective combination therapies and the significance of updated treatment guidelines. They also examine pharmacokinetics, particularly the efficacy of tetracyclines and fluoroquinolones, while emphasizing the importance of tailored approaches for vulnerable patient populations.
Stenotrophomonas maltophilia is an opportunistic pathogen increasingly recognized in nosocomial infections, posing significant treatment challenges due to intrinsic antibiotic resistance.
The primary treatment for S. maltophilia infections is trimethoprim-sulfamethoxazole, but its clinical efficacy is variable due to emerging resistance patterns.
Combination therapy is often recommended for serious infections caused by S. maltophilia, emphasizing the importance of susceptibility testing to guide effective treatment strategies.
Deep dives
Overview of Stenotrophomonas maltophilia
Stenotrophomonas maltophilia is an aerobic, catalase-positive, oxidase-negative, gram-negative bacterium recognized for its environmental ubiquity, commonly found in soil, water, plants, and contaminated medical devices. Initially identified as Bacterium bucchere in 1943, it underwent several reclassifications before settling on its current nomenclature in 1993. Despite its presence in various settings, this organism is generally of low virulence, often colonizing non-sterile sites like the human respiratory tract or chronic wounds rather than causing true infections. Notably, S. maltophilia is an opportunistic pathogen mostly affecting patients with compromised immune systems or underlying health conditions, showcasing a significant resilience due to its extensive intrinsic antibiotic resistance mechanisms.
Epidemiology and Clinical Impact
Stenotrophomonas maltophilia has become more prevalent in clinical settings over the past two decades, increasingly identified as a significant nosocomial pathogen. It accounts for approximately 1.6% to 6.3% of all respiratory tract infections and is often associated with hospitalized patients, particularly those with cystic fibrosis and chronic obstructive pulmonary disease (COPD). Bloodstream infections involving S. maltophilia represent about 1% of overall cases, frequently linked to catheter utilizations and can manifest in polymicrobial infections. Recent data suggests a steady rise in the incidence of this organism, emphasizing the need for careful identification and susceptibility testing in affected populations.
Treatment Options and Challenges
The treatment of infections caused by Stenotrophomonas maltophilia poses significant challenges due to the organism's widespread intrinsic resistance to many antibiotics. Trimethoprim-sulfamethoxazole remains the drug of choice, showing over 90% in vitro susceptibility; however, clinical efficacy can be questionable based on emerging resistance patterns. Other potential options include minocycline, often administered at high doses to achieve therapeutic concentrations, though resistance and susceptibility are variable. Ceftazidime-avibactam and ceftazidime plus aztreonam have been studied for effectively treating multidrug-resistant strains, but clinicians should always consider the unique resistance mechanisms associated with specific S. maltophilia isolates.
Recent Guidelines and Recommendations
Recent clinical guidelines suggest that, given the complexities and variable resistance profiles of Stenotrophomonas maltophilia, combination therapy is often warranted in severe or serious infections. This could involve using two active agents such as trimethoprim-sulfamethoxazole combined with minocycline or newer options like cefideracol and aztreonam. Importantly, the updated recommendations emphasize the need for susceptibility testing to guide effective treatment strategies, as empirical therapy may not be adequate due to emerging resistance. The guidelines also advocate for vigilance in differentiating between colonization and true infection, as many patients may be asymptomatic carriers that do not require antibiotic therapy.
Emerging Resistance and Future Directions
The emergence of resistance in Stenotrophomonas maltophilia is a growing concern, particularly in the context of observed rising resistance rates to commonly used antibiotics. Established treatment paradigms are challenged as laboratories report increasing instances of non-susceptible strains, often requiring clinicians to adapt their therapeutic approaches. Research is ongoing to better understand the genetic mechanisms behind the resistance and the evolution of different S. maltophilia clades, which could help identify those more prone to causing infections. Future clinical studies are essential to clarify effective treatment protocols and refine susceptibility testing methods to better address this versatile and formidable pathogen.
Drs. Amy Mathers and Julie Ann Justo join Dr. Erin McCreary to talk all things Stenotrophomonas maltophilia, a water-loving organism and frequent colonizer. Hear from the experts on why this organism is so difficult to treat, which agents have in vitro activity, and how to optimize antimicrobial regimens, including the use of combination therapy, in the setting of true infections. This medical education was provided by an unrestricted grant from Shionogi.
References:
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024 Aug 7:ciae403. doi: 10.1093/cid/ciae403. PMID: 39108079.
Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist. 2022 May 5;4(3):dlac040. doi: 10.1093/jacamr/dlac040. PMID: 35529051.
Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. Clin Infect Dis. 2021 May 4;72(9):1507-1513. doi: 10.1093/cid/ciaa778. PMID: 32544947.
An Overview of the Treatment of Less Common Non–Lactose-Fermenting Gram-Negative Bacteria. Pharmacotherapy. 2020 Sep;40(9):936-951. doi: 10.1002/phar.2447. PMID: 32687670.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode